At this time DENGVAXIA vaccine effectiveness is unknown, as effectiveness is based on real-world data of how the vaccine works in the general population, and DENGVAXIA has just been recently licensed and recommended for use in limited populations in U.S. Territories and Freely Associated States.
However, vaccine efficacy for DENGVAXIA vaccine is known and based on ideal situations like well-designed clinical trials. Notably, vaccine efficacy can differ from vaccine effectiveness because a vaccine may not work as well in the real world. Understanding what efficacy and effectiveness mean is also important. Below is an example from Yale Medicine.
“An example: Imagine there were 100 people in the vaccine group, and 100 people in the placebo group. If 10 people in the placebo group became infected, but only 2 in the vaccine group got sick, that means the vaccine has reduced the chances of illness by 80%; thus, it is considered to have an efficacy of 80%.”
According to studies funded by Sanofi Pasteur, the overall efficacy of DENGVAXIA against symptomatic laboratory confirmed dengue, hospitalization for dengue, and severe dengue is 82 percent, 79 percent, and 84 percent respectively. Sanofi Pasteur also notes a vaccine efficacy of 67 percent against both dengue type 1 and type 2, 80 percent against dengue type 3, and 89 percent against dengue type 4.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Dengue and the Dengue vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
